Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus HYDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE INTENSOL versus HYDROFLUMETHIAZIDE.
HYDROCHLOROTHIAZIDE INTENSOL vs HYDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule, reducing sodium and chloride reabsorption and increasing water excretion.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
25-100 mg orally once daily or in divided doses. Titrate based on response; maximum 200 mg/day.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
None Documented
None Documented
Terminal half-life 6–15 hours (mean ~10 hours); prolonged in renal impairment (creatinine clearance <30 mL/min) and elderly.
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Primarily renal (≥95% as unchanged drug); negligible biliary/fecal elimination (<5%).
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."